Kite Pharma (KITE) Commences KTE-C19 Combo Phase 1b/2 Combination Study in DLBCL (RHHBY)
Tweet Send to a Friend
Kite Pharma, Inc. (Nasdaq: KITE) announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
